Industry
Biotechnology
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 26, 2024 | 11:39 am
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 11:46 am
Portfolio Pulse from Benzinga Newsdesk
June 20, 2024 | 5:40 pm
Portfolio Pulse from Avi Kapoor
June 20, 2024 | 5:26 pm
Portfolio Pulse from Benzinga Insights
June 20, 2024 | 4:32 pm
Portfolio Pulse from Benzinga Newsdesk
June 20, 2024 | 10:35 am
Portfolio Pulse from Avi Kapoor
June 14, 2024 | 6:13 pm
Portfolio Pulse from Benzinga Insights
June 14, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Insights
June 12, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Newsdesk
June 11, 2024 | 10:43 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.